SynthesisEndocrine2026
Glycemic control and weight loss benefits of fixed-ratio combinations of basal insulins and GLP1 receptor agonists in type 2 diabetes: A systematic review and network meta-analysis.
Synthesis in Endocrine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo compare glycemic and weight effects of fixed-ratio combinations (FRCs) of basal insulin (BI) and glucagon-like peptide-1 receptor agonists (GLP1RAs) in adults with type 2 diabetes (T2D).
methodsRandomized controlled trials of BI-GLP1RA FRCs in adults with T2D were identified across major databases through 20 December 2025. Co-primary outcomes were changes in glycated hemoglobin (HbA1c) and body weight. A frequentist random-effects network meta-analysis, with BI as the reference, was conducted in R using netmeta. Certainty was assessed using Confidence in Network Meta-Analysis (CINeMA).
resultsThirty trials involving 17,862 participants were included. All FRCs reduced HbA1c and body weight more than BI alone. For HbA1c, HR17031 had the largest estimated reduction (mean difference [MD]: -0.72%), followed by IDegLira (-0.64%) and iGlarLixi (-0.53%). For body weight, IcoSema had the largest estimated reduction (-3.16 kg), followed by HR17031 (-1.74 kg) and IDegLira (-1.65 kg). No HR17031 comparison with other FRCs was statistically significant for either co-primary outcome; its ranking is hypothesis-generating. Excluding the high-risk-of-bias trial produced broadly consistent estimates. Compared with BI, FRCs increased achievement of HbA1c < 7%, often without weight gain or clinically significant/severe hypoglycemia. CINeMA indicated predominantly low- to moderate-certainty evidence for FRC versus BI comparisons and low- to very low-certainty evidence for many indirect comparisons among active regimens.
conclusionsBI-GLP1RA FRCs improve glycemic control and weight outcomes compared with BI alone. Rankings and apparent differences among FRCs or versus other active regimens warrant cautious interpretation given heterogeneity, inconsistency, and limited certainty of indirect evidence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.